Changing trends in serotypes of S. pneumoniae isolates causing invasive and non-invasive diseases in unvaccinated population in Mexico (2000-2014)

Carnalla-Barajas, María Noemí; Soto-Noguerón, Araceli; Sánchez-Alemán, Miguel Ángel; Solórzano-Santos, Fortino; Velázquez-Meza, María Elena; Echániz-Avilés, Gabriela; Márquez-Díaz, Francisco; Martínez-Medina, Lucila; Olvera-Herrera, Maria Elizabeth; Novales, María Guadalupe Miranda; Camacho-Velázquez, Martha; Vásquez-Rosales, José Guillermo; Vázquez-Larios, Rosario; Rivera-Martínez, Eduardo; Hernández-Dueñas, Ana María del Rocío; López-Martı́nez, Briceida; Moreno-Espinoza, Sarbelio; Calderón-Jaimes, Ernesto; Jiménez-Tapia, Yolanda; Arredondo-Garcı́a, José Luis; Macías-Parra, Mercedes; Arzate-Barbosa, Patricia; González-Saldaña, Napoleón; Sifuentes–Osornio, José; León-Garduño, Alfredo Ponce de; de, Ana Lilia Rolón-Montes; Martínez-Gamboa, Rosa Areli; Volkow-Fernández, Patricia; Cornejo‐Juárez, Patricia; Feliciano-Guzmán, José Manuel; López-Ovilla, Ismelda; Barajas-Magallón, Juan Manuel; Vazquez-Narvaez, Jorge; Cendejas-Amezcua, Alejandra; Magaña-Miranda, María del Rosario; Santos, Andrés Flores; Magaña-Aquino, Martín; Luévanos-Velázquez, Antonio; Morfín‐Otero, Rayo; Rodríguez-Noriega, Eduardo; Esparza-Ahumada, Sergio; Atilano-Durán, Guadalupe; Re-Montaño, Norma de la; Anchondo-Martínez, Martha; Contreras-Soto, Jesús; Quintero-Grijalva, Ana Dolores; Ayala-Aguilar, Jacobo; Guajardo-Lara, Claudia Elena; Garza‐González, Elvira; Rincón-Zuno, oaquín; Sánchez-Francia, Domingo; Andrade-Almaraz, Verónica; Corte-Rojas, Reyna Edith; Gutierrez-Rodríguez, María del Socorro; Anzurez-Gutiérrez, Socorro Azarell; Mosqueda, Juan L.; Gil-Veloz, Mariana; Castellanos-Martínez, Javier; Tinoco-Favila, Juan Carlos; Salcido-Gutiérrez, Lorena; Jarillo-Medina, Rosalía; Bazán, Jessica Paola-Purizaca; Aguilar-Escobar, Dinora; Méndez-Cruz, Ana Rosa; Pacheco-Gil, Leova; Acevedo-Casarrubias, Edgardo S.; González-Hernandez, Alma Rosa; Molina, María del Carmen Alvarez; Ibarra-Muñiz, Manuel; Mora-Dominguez, Paul

doi:10.1016/j.ijid.2017.02.005

Cited by 15 publications

(12 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are significant advantages of using lambs to model RSV infection as a correlate for human infants-including the ability to use human viral strains without adaptation and the similarity of the pathological sequelae [30,31]. Serotype 22F is thought to have appeared after the introduction of the S. pneumoniae vaccine PCV7 ( [44]). While this serotype was not widespread in those subsequent years ( [44]), 22F is now the second most common serotype causing invasive disease in children less than seven years old and the primary cause in the elderly [45].…”

Section: Discussionmentioning

confidence: 99%

“…Serotype 22F is thought to have appeared after the introduction of the S. pneumoniae vaccine PCV7 ( [44]). While this serotype was not widespread in those subsequent years ( [44]), 22F is now the second most common serotype causing invasive disease in children less than seven years old and the primary cause in the elderly [45]. Molecular analysis of this serotype also indicates six different lineages and 18% of clinical isolates demonstrating erythromycin resistance ( [19]).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Streptococcus pneumoniae serotype 22F infection in respiratory syncytial virus infected neonatal lambs enhances morbidity

et al. 2021

View full text Add to dashboard Cite

Respiratory syncytial virus (RSV) is the primary cause of viral bronchiolitis resulting in hospitalization and a frequent cause of secondary respiratory bacterial infection, especially by Streptococcus pneumoniae (Spn) in infants. While murine studies have demonstrated enhanced morbidity during a viral/bacterial co-infection, human meta-studies have conflicting results. Moreover, little knowledge about the pathogenesis of emerging Spn serotype 22F, especially the co-pathologies between RSV and Spn, is known. Here, colostrum-deprived neonate lambs were divided into four groups. Two of the groups were nebulized with RSV M37, and the other two groups were mock nebulized. At day three post-RSV infection, one RSV group (RSV/Spn) and one mock-nebulized group (Spn only) were inoculated with Spn intratracheally. At day six post-RSV infection, bacterial/viral loads were assessed along with histopathology and correlated with clinical symptoms. Lambs dually infected with RSV/Spn trended with higher RSV titers, but lower Spn. Additionally, lung lesions were observed to be more frequent in the RSV/Spn group characterized by increased interalveolar wall thickness accompanied by neutrophil and lymphocyte infiltration and higher myeloperoxidase. Despite lower Spn in lungs, co-infected lambs had more significant morbidity and histopathology, which correlated with a different cytokine response. Thus, enhanced disease severity during dual infection may be due to lesion development and altered immune responses rather than bacterial counts.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Streptococcus pneumoniae serotype 22F infection in respiratory syncytial virus infected neonatal lambs enhances morbidity

et al. 2021

View full text Add to dashboard Cite

show abstract

“…There are significant advantages of using lambs to model RSV infection as a correlate for human infants -including the ability to use human viral strains without adaptation and the similarity of the pathological sequelae [24,25]. Serotype 22F is thought to have appeared after the introduction of the S. pneumoniae vaccine PCV7 ( [37]). While this serotype was not widespread in those subsequent years ( [37]), 22F is now the second most common serotype causing invasive disease in children less than seven years old and the primary cause in the elderly [38].…”

Section: Rsv Infection Of Lamb Phagocytes Are Permissivementioning

confidence: 99%

“…Serotype 22F is thought to have appeared after the introduction of the S. pneumoniae vaccine PCV7 ( [37]). While this serotype was not widespread in those subsequent years ( [37]), 22F is now the second most common serotype causing invasive disease in children less than seven years old and the primary cause in the elderly [38]. Molecular analysis of this serotype also indicates six different lineages and 18% of clinical isolates demonstrating erythromycin resistance ( [18]).…”

Section: Rsv Infection Of Lamb Phagocytes Are Permissivementioning

confidence: 99%

STREPTOCOCCUS PNEUMONIAESEROTYPE 22F INFECTION IN RESPIRATORY SYNCYTIAL VIRUS INFECTED NEONATAL LAMBS ENHANCES MORBIDITY

Alnajjar

Sitthicharoenchai

Gallup

et al. 2020

Preprint

View full text Add to dashboard Cite

Respiratory syncytial virus (RSV) is the primary cause of viral bronchiolitis resulting in hospitalization and a frequent cause of secondary respiratory bacterial infection, especially by Streptococcus pneumoniae (Spn) in infants. While murine studies have demonstrated enhanced morbidity during a viral/bacterial co-infection, human meta-studies have conflicting results. Moreover, little knowledge about the pathogenesis of emerging Spn serotype 22F, and especially the co-pathologies between RSV and Spn is known. Here, colostrum-deprived neonate lambs were divided into four groups. Two of the groups were nebulized with RSV M37, and the other two groups mock nebulized. At day 3 post-infection, one RSV group (RSV/Spn) and one mocknebulized group (Spn only) were inoculated with Spn intratracheally. At day 6 post-infection, bacterial/viral loads were assessed along with histopathology and correlated with clinical symptoms. Lambs dually infected with RSV/Spn had higher RSV titers, but lower Spn.Additionally, lung lesions were observed to be more intense in the RSV/Spn group characterized by increased interalveolar wall thickness accompanied by neutrophil and lymphocyte infiltration.Despite lower Spn in lungs, co-infected lambs had more significant morbidity and histopathology, which correlated with a different cytokine response. Thus, enhanced disease severity during dual infection may be due to lesion development and altered immune responses rather than bacterial counts.

show abstract

“…However, detection of emerging new serotypes in the late PCV7 period led to the inclusion of six additional serotypes in the new PCV13 in 2010. Since then, decreases in invasive pneumococcal disease (IPD), not only in children but also in adults due to herd effect [ 24 – 27 ], as well as in PCV13 serotypes involved in non-invasive diseases, have been described [ 25 , 27 ]. Although some studies [ 28 – 30 ], but not others [ 24 , 31 ], have found slight increases in non-PCV13 serotypes causing IPD, individually none of the non-PCV13 serotypes has shown a significant increase [ 32 ], in contrast to the increase in serotype 19A (with its associated resistant sequence types [ 33 ]) after PCV7 implementation [ 33 – 35 ].…”

Section: Pharmacoepidemiology Of Resistances In Human-adapted Respiramentioning

confidence: 99%

Revisiting cefditoren for the treatment of community-acquired infections caused by human-adapted respiratory pathogens in adults

Giménez¹,

Aguilar²,

Granizo

2018

Multidiscip Respir Med

View full text Add to dashboard Cite

Fifteen years after its licensure, this revision assesses the role of cefditoren facing the current pharmacoepidemiology of resistances in respiratory human-adapted pathogens (Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae and Moraxella catarrhalis). In the era of post- pneumococcal conjugate vaccines and in an environment of increasing diffusion of the ftsI gene among H. influenzae isolates, published studies on the cefditoren in vitro microbiological activity, pharmacokinetic/pharmcodynamic (PK/PD) activity and clinical efficacy are reviewed. Based on published data, an overall analysis is performed for PK/PD susceptibility interpretation. Further translation of PK/PD data into clinical/microbiological outcomes obtained in clinical trials carried out in the respiratory indications approved for cefditoren in adults (tonsillitis, sinusitis, acute exacerbation of chronic bronchitis and community-acquired pneumonia) is commented. Finally, the role of cefditoren within the current antibiotic armamentarium for the treatment of community respiratory tract infections in adults is discussed based on the revised information on its intrinsic activity, pharmacodynamic adequacy and clinical/bacteriological efficacy. Cefditoren remains an option to be taken into account when selecting an oral antibiotic for the empirical treatment of respiratory infections in the community caused by human-adapted pathogens, even when considering changes in the pharmacoepidemiology of resistances over the last two decades.

show abstract

Changing trends in serotypes of S. pneumoniae isolates causing invasive and non-invasive diseases in unvaccinated population in Mexico (2000-2014)

Cited by 15 publications

References 22 publications

Streptococcus pneumoniae serotype 22F infection in respiratory syncytial virus infected neonatal lambs enhances morbidity

Streptococcus pneumoniae serotype 22F infection in respiratory syncytial virus infected neonatal lambs enhances morbidity

STREPTOCOCCUS PNEUMONIAESEROTYPE 22F INFECTION IN RESPIRATORY SYNCYTIAL VIRUS INFECTED NEONATAL LAMBS ENHANCES MORBIDITY

Revisiting cefditoren for the treatment of community-acquired infections caused by human-adapted respiratory pathogens in adults

Contact Info

Product

Resources

About